ECRAID-Prime Welcomes Georgia: Latest Study Milestones & Updates
The ECRAID-Prime trial is thrilled to welcome Georgia as its latest participating country, marking another milestone with the enrolment of its first patient locally. Following its recent activation, Georgia is now part of the ECRAID-Prime expanding family.
With 300 participants enrolled across eight countries so far, the EU-funded study aims to reach 1,000 for the evaluation of NONS and Saline as potential treatments for COVID-19 and similar respiratory infections by the end of 2026. Meanwhile, preparations are underway for a protocol amendment to include a new compound, LTX-109, in the active adaptive platform trial in Q3 this year
First Patient Last Visit Milestone: Germany and France
Germany and France have reached an important milestone: their first participants, enrolled in October last year, have successfully completed their study journeys from Day 1 to Month 6, with France’s last phone call appointment with their participant to take place in the coming weeks.
At the University Hospital in Würzburg in Germany, Ildikó Gágyor, highlights the dedication of her team, emphasising teamwork and close collaboration with their local general practitioners (GPs). “Reaching this milestone marks the completion of a significant part of the study, and this is a result of good teamwork.”
However, she acknowledges that recruitment remains a major challenge, and her team is exploring new ways to increase participant enrolment.
At the University Hospital in Würzburg in Germany, Ildikó Gágyor, highlights the dedication of her team, emphasising teamwork and close collaboration with their local general practitioners (GPs). “Reaching this milestone marks the completion of a significant part of the study, and this is a result of good teamwork.”
However, she acknowledges that recruitment remains a major challenge, and her team is exploring new ways to increase participant enrolment.
“Here in Germany, we visit our participants at home for study inclusion. Being welcomed into their private lives reflects deep trust in the doctor-patient relationships, and we are grateful to be part of this. We’re always happy to hear a patient is interested in participating in the study – together, we can make a difference!”
- Ildikó Gágyor, general practitioner and head of the General Practice department at the University Hospital in Würzburg.
In France, Elodie Pfender and her team at CHU Limoges are celebrating the upcoming completion of their first participant’s final follow-up phone call, set to take place in the next two weeks. The team, who included the study’s very first patient last year, is excited to reach this milestone. “This would be a real achievement in our collaborative adventure!” she smiles.
Reflecting on the participant’s six-month journey, Elodie shares her key insights.
“The experience with our first participant was a real success – everything went smoothly and positively. She was very enthusiastic about the opportunity to contributing to clinical research, and especially appreciated the quality and friendliness of our study team’s follow-up calls.”
- Elodie Pfender, Co-head of the Clinical investigational Center at CHU Limoges.
To ensure a seamless experience, the team prioritised simplifying logistics for both its participating GPs and their patients. “We make sure that the team is always available to answer our participants’ questions and offer regular support – particularly by phone, to help them complete their follow-up diaries and track their doses.”
She adds, “However, there's still a long way to go. To date, 30% of planned participants have been included in France, but our team is committed to maintaining this momentum!”
Read more about the NONS study.